Influenza A, Influenza B
Conditions
Brief summary
The primary purpose of this study is to validate the sensitivity and specificity of the Respirio Flu Test in detecting Influenza A, when used by subjects, as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). The secondary aims are to: * validate the sensitivity and specificity of the Respirio Flu Test in detecting Influenza B , when used by subjects, as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). * assess agreement (positive and negative) between Respirio Flu Test and Sofia® Influenza A+B Test in detecting Influenza A; * assess agreement (positive and negative) between Respirio Flu Test and Sofia® Influenza A+B Test in detecting Influenza B; * evaluate the correct interpretation of the Respirio Flu Test results by subjects with Influenza-like illness symptoms; * evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the Respirio Flu Test; * evaluate the subjects' comprehension of the Respirio Flu Test labelling; and * establish the minimum sample weight required to achieve a result with the Respirio Flu Test.
Interventions
DEVICERespirio Flu Test
The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
DEVICESofia® Influenza A+B Fluorescent Immunoassay (FIA)
Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
Sponsors
Ellume Pty Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female subjects aged ≥ 1 year; * Rhinorrhea; * ≤ 72 hours from onset of Influenza-like illness symptoms; * Subject (or parent/legal guardian) capable and willing to give informed consent/assent. * Subject (or parent/legal guardian) able to read and write in English.
Exclusion criteria
* Has undergone treatment with antivirals within the previous 7 days; * Has been vaccinated by means of an Influenza nasal spray/mist vaccine within the previous 7 days; * Recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months; * Currently enrolled in another clinical trial or used any investigational device within 90 days preceding informed consent; * Has had prior exposure to the Respirio Flu Test; * Subject (or parent/legal guardian) residing at the same residential address as a subject currently enrolled in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Of participants positive for influenza A by ReverseTranscriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by Respirio Flu Test. | Day 1 | Establish sensitivity against a gold standard. Report as a percentage of participants with 95% confidence limits. |
| Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by Respirio Flu Test. | Day 1 | Establish specificity against a gold standard. Report as a percentage of participants with 95% confidence limits. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent of participants positive for influenza A by Sofia® Influenza A+B Test and Respirio Flu Test. | Day 1 | Establish positive agreement against an imperfect standard. Report as a percentage of participants with 95% confidence limits. |
| Percent of participants negative for influenza B by Sofia® Influenza A+B Test and Respirio Flu Test. | Day 1 | Establish negative agreement against an imperfect standard. Report as a percentage of participants with 95% confidence limits. |
| Combine positive and negative agreement of Respirio Flu Test and Sofia® Influenza A+B Test to establish overall agreement. Report as a percentage of participants with 95% confidence limits. | Day 1 | — |
| Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by Respirio Flu Test. | Day 1 | Establish sensitivity against a gold standard. Report as a percentage of participants with 95% confidence limits. |
| Scores from questionnaire to assess ease of use, comfort and convenience of Respirio Flu Test. | Day 1 | The ease of use questionnaire will provide the following: • Total number of responses to each question and the percentage of participants selecting each response (most on a 5 point Likert scale). |
| Percent of participants correctly determining eligibility and conditions for use of Respirio Flu Test from scores on a label comprehension questionnaire. | Day 1 | The label comprehension questionnaire will provide the following data * Total number of responses to the question and the percentage of participants selecting each option. * Number and percentage of participants selecting the correct answer to each question. * Overall percentage of patients with an acceptable level of comprehension. |
| Weight of sample deposited in Respirio Flu Test. | Day 1 | Establish minimum weight of sample required to obtain a valid result from the Respirio Flu Test. |
| Percent of participants who correctly interpret result of Respirio Flu Test. | Day 1 | Agreement between trained staff and participants. Report as a percentage of participants with 95% confidence limits. |
| Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by Respirio Flu Test. | Day 1 | Establish specificity against a gold standard. Report as a percentage of participants with 95% confidence limits. |
Countries
Australia
Outcome results
None listed